Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian
Description
In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed:
1. ASC4FIRST RCT: Asciminib in newly diagnosed CML.
https://pubmed.ncbi.nlm.nih.gov/38820078/
2. 5-year follow-up of ENESTnd RCT (nilotinib):
https://pubmed.ncbi.nlm.nih.gov/26837842/
3. 10-year follow-up of ENESTnd RCT (nilotinib):
https://pubmed.ncbi.nlm.nih.gov/33414482/
4. 10-year follow-up of CML-IV RCT (imatinib):
https://pubmed.ncbi.nlm.nih.gov/25676422/
5. MD Anderson data on low-dose dasatinib (50 mg):
https://pubmed.ncbi.nlm.nih.gov/36054032/
https://pubmed.ncbi.nlm.nih.gov/31553487/
6. CML: 2025 update on diagnosis, therapy, and monitoring:
https://pubmed.ncbi.nlm.nih.gov/39093014/
United States
